Stratos Wealth Partners LTD. Lowers Stock Position in GSK plc (NYSE:GSK)

Stratos Wealth Partners LTD. trimmed its holdings in shares of GSK plc (NYSE:GSK) by 11.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,007 shares of the pharmaceutical company’s stock after selling 2,111 shares during the quarter. Stratos Wealth Partners LTD.’s holdings in GSK were worth $541,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Sivia Capital Partners LLC acquired a new stake in GSK in the third quarter worth about $209,000. Creative Planning raised its position in shares of GSK by 3.9% in the 3rd quarter. Creative Planning now owns 211,100 shares of the pharmaceutical company’s stock valued at $8,630,000 after purchasing an additional 7,854 shares during the last quarter. Foster Victor Wealth Advisors LLC boosted its stake in GSK by 5.0% in the 3rd quarter. Foster Victor Wealth Advisors LLC now owns 272,917 shares of the pharmaceutical company’s stock worth $10,982,000 after purchasing an additional 13,045 shares in the last quarter. Jamison Private Wealth Management Inc. grew its position in GSK by 4.6% during the 3rd quarter. Jamison Private Wealth Management Inc. now owns 17,849 shares of the pharmaceutical company’s stock worth $730,000 after purchasing an additional 784 shares during the last quarter. Finally, Roberts Wealth Advisors LLC increased its stake in GSK by 2.1% during the 3rd quarter. Roberts Wealth Advisors LLC now owns 85,376 shares of the pharmaceutical company’s stock valued at $3,246,000 after purchasing an additional 1,760 shares in the last quarter. Institutional investors own 15.74% of the company’s stock.

Wall Street Analysts Forecast Growth

GSK has been the subject of a number of recent research reports. Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and reduced their price objective for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Finally, Guggenheim lowered shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Six research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company. According to MarketBeat, GSK has an average rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Stock Down 1.1 %

GSK stock opened at $36.07 on Wednesday. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.53 and a current ratio of 0.78. The stock’s fifty day moving average is $34.29 and its two-hundred day moving average is $37.53. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.92. The firm has a market capitalization of $74.75 billion, a price-to-earnings ratio of 22.68, a price-to-earnings-growth ratio of 1.42 and a beta of 0.64.

GSK (NYSE:GSK) last released its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. Analysts predict that GSK plc will post 4.07 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be given a dividend of $0.3932 per share. This represents a $1.57 dividend on an annualized basis and a yield of 4.36%. The ex-dividend date of this dividend is Friday, February 21st. This is an increase from GSK’s previous quarterly dividend of $0.39. GSK’s dividend payout ratio is 93.08%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.